Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.

ABSTRACT: Advances in multiagent chemotherapy have led to recent improvements in survival for patients with acute lymphoblastic leukemia (ALL); however, a significant fraction do not respond to frontline chemotherapy or later relapse with recurrent disease, after which long-term survival rates remain low. To develop new, effective treatment options for these patients, we conducted a series of high-throughput combination drug screens to identify chemotherapies that synergize in a lineage-specific manner with MRX-2843, a small molecule dual MERTK and FLT3 kinase inhibitor currently in clinical testing for treatment of relapsed/refractory leukemias and solid tumors. Using experimental and computational approaches, we found that MRX-2843 synergized strongly-and in a ratio-dependent manner-with vincristi

SUBMITTER: Kelvin JM 

PROVIDER: S-EPMC10544718 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature